(Q37714992)

22 August 2017

1 reference

title

Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease (English)

1 reference

22 August 2017

0 references

0 references

3

1 reference

22 August 2017

4

Mark A Smith

1 reference

22 August 2017

Gang Liu

1

1 reference

PubMed ID

20302830

22 August 2017

Ping Men

series ordinal

2

1 reference

22 August 2017

8 December 2009

1 reference

Progress in Brain Research

22 August 2017

1 reference

22 August 2017

180

1 reference

22 August 2017

97-108

1 reference

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Vitamin E protects nerve cells from amyloid beta protein toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Iron: a pathological mediator of Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Rapid induction of Alzheimer A beta amyloid formation by zinc.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Neuropathology of Alzheimer disease: pathognomonic but not pathogenic

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Iron: the Redox-active center of oxidative stress in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Therapeutic approaches to protein-misfolding diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Intramuscular desferrioxamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Therapeutic treatments for Alzheimer's disease based on metal bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Effects of chelators on iron uptake and release by the brain in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Free radicals in brain metabolism and pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta_{42} in senile plaque cores in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Global prevalence of dementia: a Delphi consensus study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Alzheimer's disease: the amyloid cascade hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction†

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Fullerene inhibits beta-amyloid peptide aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Aluminum(III) facilitates the oxidation of NADH by the superoxide anion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Nanoparticulate systems for brain delivery of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Amyloid beta: the alternate hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Nanoparticle and other metal chelation therapeutics in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Copper, iron and zinc in Alzheimer's disease senile plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Oxidative stress hypothesis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Therapeutic opportunities in Alzheimer disease: one for all or all for one?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Oxidative damage is the earliest event in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

An introduction to the free radical hypothesis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Blood-brain barrier delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Treatment of Alzheimer's disease with clioquinol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Redox-active iron mediates amyloid-beta toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Redox metals and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

The role of iron in beta amyloid toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

The molecular pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

1 reference

7 January 2021

Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss!

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Amyloid-β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Radical AGEing in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Inhibitors of fibril formation and cytotoxicity of beta-amyloid peptide composed of KLVFF recognition element and flexible hydrophilic disrupting element.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

TiO2 nanoparticles promote beta-amyloid fibrillation in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

1 reference

7 January 2021

Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2808%2980005-2

7 January 2021

10.1016/S0079-6123(08)80005-2

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20302830